American International Group’s Aldeyra Therapeutics ALDX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-22,952
Closed -$75.1K 99
2024
Q1
$75.1K Sell
22,952
-197
-0.9% -$648 ﹤0.01% 2664
2023
Q4
$81.3K Sell
23,149
-94
-0.4% -$290 ﹤0.01% 2667
2023
Q3
$155K Buy
23,243
+826
+4% +$6.13K ﹤0.01% 2257
2023
Q2
$188K Buy
+22,417
New +$221K ﹤0.01% 2208
2022
Q2
Sell
-24,096
Closed -$107K 3089
2022
Q1
$107K Sell
24,096
-1,696
-7% -$6.76K ﹤0.01% 2568
2021
Q4
$103K Sell
25,792
-771
-3% -$5.88K ﹤0.01% 2700
2021
Q3
$233K Sell
26,563
-632
-2% -$5.8K ﹤0.01% 2342
2021
Q2
$308 Buy
+27,195
New +$327K ﹤0.01% 2239
2020
Q2
Sell
-13,576
Closed -$34K 3108
2020
Q1
$34K Sell
13,576
-784
-5% -$3.53K ﹤0.01% 2813
2019
Q4
$83K Buy
14,360
+118
+0.8% +$682 ﹤0.01% 2716
2019
Q3
$75K Sell
14,242
-98
-0.7% -$528 ﹤0.01% 2743
2019
Q2
$86K Buy
14,340
+868
+6% +$6.53K ﹤0.01% 2757
2019
Q1
$122K Sell
13,472
-437
-3% -$3.71K ﹤0.01% 2506
2018
Q4
$115K Buy
13,909
+2,641
+23% +$27.1K ﹤0.01% 2515
2018
Q3
$155K Buy
11,268
+895
+9% +$7.26K ﹤0.01% 2574
2018
Q2
$82K Buy
+10,373
New +$82.8K ﹤0.01% 2870

Other funds holding ALDX

American International Group's ALDX Position: Q2 2024 in Review

American International Group sold out of Aldeyra Therapeutics (ALDX) in Q2 2024, closing a stake of 22,952 shares — an estimated $75.1K sold.

American International Group first reported a position in ALDX in Q2 2018 and held it in 16 quarters. The position peaked at $233K in Q3 2021. 103 funds tracked by Wall St. Rank hold ALDX as of Q2 2024.

  • American International Group reported no remaining Aldeyra Therapeutics position as of Q2 2024 after selling out during the quarter.
  • American International Group sold 22,952 Aldeyra Therapeutics shares in Q2 2024, an estimated $75.1K.
  • American International Group first reported a position in Aldeyra Therapeutics in Q2 2018 and held it in 16 quarters.
  • American International Group's Aldeyra Therapeutics position peaked at $233K in Q3 2021.
  • 103 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2024.

Based on American International Group's 13F filing for Q2 2024, filed 13 Aug 2024.